ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. **NAME OF THE MEDICINAL PRODUCT**

Tremfya 100 mg solution for injection in pre-filled syringe
Tremfya 100 mg solution for injection in pre-filled pen

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Tremfya 100 mg solution for injection in pre-filled syringe

Each pre-filled syringe contains 100 mg of guselkumab in 1 mL solution.

Tremfya 100 mg solution for injection in pre-filled pen

Each pre-filled pen contains 100 mg of guselkumab in 1 mL solution.

Guselkumab is a fully human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody (mAb) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Solution for injection (injection)

The solution is clear and colourless to light yellow.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

**Plaque psoriasis**

Tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

**Psoriatic arthritis**

Tremfya, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy (see section 5.1).

4.2 **Posology and method of administration**

This medicinal product is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which it is indicated.

**Posology**

*Plaque psoriasis*

The recommended dose is 100 mg by subcutaneous injection at weeks 0 and 4, followed by a maintenance dose every 8 weeks (q8w).

Consideration should be given to discontinuing treatment in patients who have shown no response after 16 weeks of treatment.
Psoriatic arthritis
The recommended dose is 100 mg by subcutaneous injection at weeks 0 and 4, followed by a maintenance dose every 8 weeks. For patients at high risk for joint damage according to clinical judgement, a dose of 100 mg every 4 weeks (q4w) may be considered (see section 5.1).

Consideration should be given to discontinuing treatment in patients who have shown no response after 24 weeks of treatment.

Special populations

Elderly (≥ 65 years)
No dose adjustment is required (see section 5.2).
There is limited information in subjects aged ≥ 65 years and very limited information in subjects aged ≥ 75 years (see section 5.2).

Renal or hepatic impairment
Tremfya has not been studied in these patient populations. No dose recommendations can be made. For further information on elimination of guselkumab, see section 5.2.

Paediatric population
The safety and efficacy of Tremfya in children and adolescents below the age of 18 years have not been established. No data are available.

Method of administration

Subcutaneous use. If possible, areas of the skin that show psoriasis should be avoided as injection sites.

After proper training in subcutaneous injection technique, patients may inject Tremfya if a physician determines that this is appropriate. However, the physician should ensure appropriate medical follow-up of patients. Patients should be instructed to inject the full amount of solution according to the ‘Instructions for use’ provided in the carton.
For instructions on preparation of the medicinal product before administration, see section 6.6.

4.3 Contraindications

Serious hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Clinically important active infections (e.g. active tuberculosis, see section 4.4).

4.4 Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Infections

Guselkumab may increase the risk of infection. Treatment should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.

Patients treated with guselkumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection or is not responding to standard therapy, the patient should be monitored closely and treatment should be discontinued until the infection resolves.
Pre-treatment evaluation for tuberculosis

Prior to initiating treatment, patients should be evaluated for tuberculosis (TB) infection. Patients receiving guselkumab should be monitored for signs and symptoms of active TB during and after treatment. Anti-TB therapy should be considered prior to initiating treatment in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

Hypersensitivity

Serious hypersensitivity reactions, including anaphylaxis, have been reported in the post-marketing setting (see section 4.8). Some serious hypersensitivity reactions occurred several days after treatment with guselkumab, including cases with urticaria and dyspnoea. If a serious hypersensitivity reaction occurs, administration of guselkumab should be discontinued immediately and appropriate therapy initiated.

Hepatic transaminase elevations

In psoriatic arthritis clinical studies, an increased incidence of liver enzyme elevations was observed in patients treated with guselkumab q4w compared to patients treated with guselkumab q8w or placebo (see section 4.8).

When prescribing guselkumab q4w in psoriatic arthritis, it is recommended to evaluate liver enzymes at baseline and thereafter according to routine patient management. If increases in alanine aminotransferase [ALT] or aspartate aminotransferase [AST] are observed and drug-induced liver injury is suspected, treatment should be temporarily interrupted until this diagnosis is excluded.

Immunisations

Prior to initiating therapy, completion of all appropriate immunisations should be considered according to current immunisation guidelines. Live vaccines should not be used concurrently in patients treated with guselkumab. No data are available on the response to live or inactive vaccines.

Before live viral or live bacterial vaccination, treatment should be withheld for at least 12 weeks after the last dose and can be resumed at least 2 weeks after vaccination. Prescribers should consult the Summary of Product Characteristics of the specific vaccine for additional information and guidance on concomitant use of immunosuppressive agents post-vaccination.

4.5 Interaction with other medicinal products and other forms of interaction

Interactions with CYP450 substrates

In a Phase 1 study in subjects with moderate to severe plaque psoriasis, changes in systemic exposures ($C_{\text{max}}$ and $AUC_{\text{inf}}$) of midazolam, S-warfarin, omeprazole, dextromethorphan, and caffeine after a single dose of guselkumab were not clinically relevant, indicating that interactions between guselkumab and substrates of various CYP enzymes (CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2) are unlikely. There is no need for dose adjustment when co-administering guselkumab and CYP450 substrates.

Concomitant immunosuppressive therapy or phototherapy

In psoriasis studies, the safety and efficacy of guselkumab in combination with immunosuppressants, including biologics, or phototherapy have not been evaluated.
4.6 Fertility, pregnancy and lactation

Women of childbearing potential

Women of childbearing potential should use effective methods of contraception during treatment and for at least 12 weeks after treatment.

Pregnancy

There are no data from the use of guselkumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/foetal development, parturition or postnatal development (see section 5.3). As a precautionary measure, it is preferable to avoid the use of Tremfya during pregnancy.

Breast-feeding

It is unknown whether guselkumab is excreted in human milk. Human IgGs are known to be excreted in breast milk during the first few days after birth, and decrease to low concentrations soon afterwards; consequently, a risk to the breast-fed infant during this period cannot be excluded. A decision should be made whether to discontinue breast-feeding or to abstain from Tremfya therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. See section 5.3 for information on the excretion of guselkumab in animal (cynomolgus monkey) milk.

Fertility

The effect of guselkumab on human fertility has not been evaluated. Animal studies do not indicate direct or indirect harmful effects with respect to fertility (see section 5.3).

4.7 Effects on ability to drive and use machines

Tremfya has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Summary of the safety profile

The most common adverse reaction was respiratory tract infections in approximately 14% of patients in the psoriasis and psoriatic arthritis clinical studies.

Tabulated list of adverse reactions

Table 1 provides a list of adverse reactions from psoriasis and psoriatic arthritis clinical studies as well as from post-marketing experience. The adverse reactions are classified by MedDRA System Organ Class and frequency, using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Table 1: List of adverse reactions

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Frequency</th>
<th>Adverse reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td>Very common</td>
<td>Respiratory tract infections</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Herpes simplex infections</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Tinea infections</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Gastroenteritis</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>Uncommon</td>
<td>Hypersensitivity</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Anaphylaxis</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Common</td>
<td>Headache</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Common</td>
<td>Diarrhoea</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue</td>
<td>Uncommon</td>
<td>Urticaria</td>
</tr>
<tr>
<td>disorders</td>
<td>Uncommon</td>
<td>Rash</td>
</tr>
<tr>
<td>Musculoskeletal and connective</td>
<td>Common</td>
<td>Arthralgia</td>
</tr>
<tr>
<td>tissue disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>General disorders and administration</td>
<td>Common</td>
<td>Injection site reactions</td>
</tr>
<tr>
<td>site conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigations</td>
<td>Common</td>
<td>Transaminases increased</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Neutrophil count decreased</td>
</tr>
</tbody>
</table>

Description of selected adverse reactions

Transaminases increased

In two Phase III psoriatic arthritis clinical studies, through the placebo-controlled period, adverse events of increased transaminases (includes ALT increased, AST increased, hepatic enzyme increased, transaminases increased, liver function test abnormal, hypertransaminasaemia) were reported more frequently in the guselkumab-treated groups (8.6% in the q4w group and 8.3% in the q8w group) than in the placebo group (4.6%). Through 1 year, adverse events of increased transaminases (as above) were reported in 12.9% of patients in the q4w group and 11.7% of patients in the q8w group.

Based on laboratory assessments, most transaminase increases (ALT and AST) were ≤ 3 x upper limit of normal (ULN). Transaminase increases from > 3 to ≤ 5 x ULN and > 5 x ULN were low in frequency, occurring more often in the guselkumab q4w group compared with the guselkumab q8w group (Table 2). A similar pattern of frequency by severity and by treatment group was observed through the end of the 2-year Phase III psoriatic arthritis clinical study.

Table 2: Frequency of patients with transaminase increases post-baseline in two Phase III psoriatic arthritis clinical studies

<table>
<thead>
<tr>
<th></th>
<th>Through week 24a</th>
<th>Through 1 yearb</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo N=370c</td>
<td>guselkumab 100 mg q8w N=373c</td>
</tr>
<tr>
<td></td>
<td>guselkumab 100 mg q8w N=373c</td>
<td>guselkumab 100 mg q4w N=371c</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;1 to ≤3 x ULN</td>
<td>30.0%</td>
<td>28.2%</td>
</tr>
<tr>
<td>&gt;3 to ≤5 x ULN</td>
<td>1.4%</td>
<td>1.1%</td>
</tr>
<tr>
<td>&gt;5 x ULN</td>
<td>0.8%</td>
<td>0.8%</td>
</tr>
<tr>
<td>AST</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;1 to ≤3 x ULN</td>
<td>20.0%</td>
<td>18.8%</td>
</tr>
<tr>
<td>&gt;3 to ≤5 x ULN</td>
<td>0.5%</td>
<td>1.6%</td>
</tr>
<tr>
<td>&gt;5 x ULN</td>
<td>1.1%</td>
<td>0.5%</td>
</tr>
</tbody>
</table>

a placebo-controlled period

b patients randomised to placebo at baseline and crossed over to guselkumab are not included
c number of patients with at least one post-baseline assessment for the specific laboratory test within the time period

In the psoriasis clinical studies, through 1 year, the frequency of transaminase increases (ALT and AST) for the guselkumab q8w dose was similar to that observed for the guselkumab q8w dose in the...
psoriatic arthritis clinical studies. Through 5 years, the incidence of transaminase elevation did not increase by year of guselkumab treatment. Most transaminase increases were ≤ 3 x ULN.

In most cases, the increase in transaminases was transient and did not lead to discontinuation of treatment.

Neutrophil count decreased
In two Phase III psoriatic arthritis clinical studies, through the placebo-controlled period, the adverse event of decreased neutrophil count was reported more frequently in the guselkumab-treated group (0.9%) than in the placebo group (0%). Through 1 year, the adverse event of decreased neutrophil count was reported in 0.9% of patients treated with guselkumab. In most cases, the decrease in blood neutrophil count was mild, transient, not associated with infection and did not lead to discontinuation of treatment.

Gastroenteritis
In two Phase III psoriasis clinical studies through the placebo-controlled period, gastroenteritis occurred more frequently in the guselkumab-treated group (1.1%) than in the placebo group (0.7%). Through Week 264, 5.8% of all guselkumab-treated patients reported gastroenteritis. Adverse reactions of gastroenteritis were non-serious and did not lead to discontinuation of guselkumab through Week 264. Gastroenteritis rates observed in psoriatic arthritis clinical studies through the placebo-controlled period were similar to those observed in the psoriasis clinical studies.

Injection site reactions
In two Phase III psoriasis clinical studies through Week 48, 0.7% of guselkumab injections and 0.3% of placebo injections were associated with injection site reactions. Through Week 264, 0.4% of guselkumab injections were associated with injection site reactions. Injection site reactions were generally mild to moderate in severity; none were serious, and one led to discontinuation of guselkumab.

In two Phase III psoriatic arthritis clinical studies through Week 24, the number of subjects that reported 1 or more injection site reactions was low and slightly higher in the guselkumab groups than in the placebo group; 5 (1.3%) subjects in the guselkumab q8w group, 4 (1.1%) subjects in the guselkumab q4w group, and 1 (0.3%) subject in the placebo group. One subject discontinued guselkumab due to an injection site reaction during the placebo-controlled period of the psoriatic arthritis clinical studies. Through 1 year, the proportion of subjects reporting 1 or more injection site reactions was 1.6% and 2.4% in the guselkumab q8w and q4w groups respectively. Overall, the rate of injections associated with injection site reactions observed in psoriatic arthritis clinical studies through the placebo-controlled period was similar to rates observed in the psoriasis clinical studies.

Immunogenicity
The immunogenicity of guselkumab was evaluated using a sensitive and drug-tolerant immunoassay.

In pooled Phase II and Phase III analyses in patients with psoriasis and psoriatic arthritis, 5% (n=145) of patients treated with guselkumab developed antidrug antibodies in up to 52 weeks of treatment. Of the patients who developed antidrug antibodies, approximately 8% (n=12) had antibodies that were classified as neutralizing, which equates to 0.4% of all patients treated with guselkumab. In pooled Phase III analyses in patients with psoriasis, approximately 15% of patients treated with guselkumab developed antidrug antibodies in up to 264 weeks of treatment. Of the patients who developed antidrug antibodies, approximately 5% had antibodies that were classified as neutralizing, which equates to 0.76% of all patients treated with guselkumab. Antidrug antibodies were not associated with lower efficacy or development of injection-site reactions.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.
4.9 Overdose

Single intravenous doses of guselkumab up to 987 mg (10 mg/kg) have been administered in healthy volunteers and single subcutaneous doses of guselkumab up to 300 mg have been administered in patients with plaque psoriasis in clinical studies without dose-limiting toxicity. In the event of overdose, the patient must be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment must be administered immediately.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Immunosuppressants, interleukin inhibitors, ATC code: L04AC16.

Mechanism of action

Guselkumab is a human IgG1λ monoclonal antibody (mAb) that binds selectively to the interleukin 23 (IL-23) protein with high specificity and affinity. IL-23 is a cytokine that is involved in inflammatory and immune responses. By blocking IL-23 from binding to its receptor, guselkumab inhibits IL-23-dependent cell signalling and release of proinflammatory cytokines.

Levels of IL-23 are elevated in the skin of patients with plaque psoriasis. In in vitro models, guselkumab was shown to inhibit the bioactivity of IL-23 by blocking its interaction with cell surface IL-23 receptor, disrupting IL-23-mediated signaling, activation and cytokine cascades. Guselkumab exerts clinical effects in plaque psoriasis and psoriatic arthritis through blockade of the IL-23 cytokine pathway.

Pharmacodynamic effects

In a Phase I study, treatment with guselkumab resulted in reduced expression of IL-23/Th17 pathway genes and psoriasis-associated gene expression profiles, as shown by analyses of mRNA obtained from lesional skin biopsies of patients with plaque psoriasis at Week 12 compared to baseline. In the same Phase I study, treatment with guselkumab resulted in improvement of histological measures of psoriasis at Week 12, including reductions in epidermal thickness and T-cell density. In addition, reduced serum IL-17A, IL-17F and IL-22 levels compared to placebo were observed in guselkumab treated patients in Phase II and Phase III plaque psoriasis studies. These results are consistent with the clinical benefit observed with guselkumab treatment in plaque psoriasis.

In psoriatic arthritis patients in Phase III studies, serum levels of acute phase proteins C-reactive protein, serum amyloid A, and IL-6, and Th17 effector cytokines IL-17A, IL-17F and IL-22 were elevated at baseline. Guselkumab decreased the levels of these proteins within 4 weeks of initiation of treatment. Guselkumab further reduced the levels of these proteins by Week 24 compared to baseline and also to placebo.

Clinical efficacy and safety

Plaque psoriasis

The efficacy and safety of guselkumab was assessed in three randomised, double-blind, active controlled Phase III studies in adult patients with moderate to severe plaque psoriasis, who were candidates for phototherapy or systemic therapy.
**VOYAGE 1 and VOYAGE 2**
Two studies (VOYAGE 1 and VOYAGE 2) evaluated the efficacy and safety of guselkumab versus placebo and adalimumab in 1829 adult patients. Patients randomised to guselkumab (N=825) received 100 mg at Weeks 0 and 4, and every 8 weeks (q8w) thereafter through Week 48 (VOYAGE 1) and Week 20 (VOYAGE 2). Patients randomised to adalimumab (N=582) received 80 mg at Week 0 and 40 mg at Week 1, followed by 40 mg every other week (q2w) through Week 48 (VOYAGE 1) and Week 23 (VOYAGE 2). In both studies, patients randomised to placebo (N=422) received guselkumab 100 mg at Weeks 16, 20 and q8w thereafter. In VOYAGE 1, all patients, including those randomised to adalimumab at Week 0, started to receive open-label guselkumab q8w at Week 52. In VOYAGE 2, patients randomised to guselkumab at Week 0 who were Psoriasis Area and Severity Index (PASI) 90 responders at Week 28 were re-randomised to either continue treatment with guselkumab q8w (maintenance treatment) or receive placebo (withdrawal treatment). Withdrawal patients re-initiated guselkumab (dosed at time of retreatment, 4 weeks later and q8w thereafter) when they experienced at least a 50% loss of their Week 28 PASI improvement. Patients randomised to adalimumab at Week 0 who were PASI 90 non-responders received guselkumab at Weeks 28, 32 and q8w thereafter. In VOYAGE 2, all patients started to receive open-label guselkumab q8w at Week 76.

Baseline disease characteristics were consistent for the study populations in VOYAGE 1 and 2 with a median body surface area (BSA) of 22% and 24%, a median baseline PASI score of 19 for both studies, a median baseline dermatology quality of life index (DLQI) score of 14 and 14.5, a baseline investigator global assessment (IGA) score of severe for 25% and 23% of patients, and a history of psoriatic arthritis for 19% and 18% of patients, respectively.

Of all patients included in VOYAGE 1 and 2, 32% and 29% were naïve to both conventional systemic and biologic therapy, 54% and 57% had received prior phototherapy, and 62% and 64% had received prior conventional systemic therapy, respectively. In both studies, 21% had received prior biologic therapy, including 11% who had received at least one anti-tumour necrosis factor alpha (TNFα) agent, and approximately 10% who had received an anti-IL-12/IL-23 agent.

The efficacy of guselkumab was evaluated with respect to overall skin disease, regional disease (scalp, hand and foot and nails) and quality of life and patient reported outcomes. The co-primary endpoints in VOYAGE 1 and 2 were the proportion of patients who achieved an IGA score of cleared or minimal (IGA 0/1) and a PASI 90 response at Week 16 versus placebo (see Table 3).

**Overall skin disease**
Treatment with guselkumab resulted in significant improvements in the measures of disease activity compared to placebo and adalimumab at Week 16 and compared to adalimumab at Weeks 24 and 48. The key efficacy results for the primary and major secondary study endpoints are shown in Table 3 below.
Table 3: Summary of clinical responses in VOYAGE 1 and VOYAGE 2

|                   | Number of patients (%) | VOYAGE 1 | | VOYAGE 2 | | adalimumab |
|-------------------|------------------------|---------|--------|---------|--------|
|                   |                        | Placebo | guselkumab | adalimumab | Placebo | guselkumab | adalimumab |
| **Placebo (N=174)** |                        |         |         |         |         |         |         |
| **guselkumab (N=329)** |                        |         |         |         |         |         |         |
| **adalimumab (N=334)** |                        |         |         |         |         |         |         |
| **Placebo (N=248)** |                        |         |         |         |         |         |         |
| **guselkumab (N=496)** |                        |         |         |         |         |         |         |
| **adalimumab (N=248)** |                        |         |         |         |         |         |         |
| **Week 16** |                        |         |         |         |         |         |         |
| PASI 75 | 10 (5.7) | 300 (91.2)a | 244 (73.1)b | 20 (8.1) | 428 (86.3)c | 170 (68.5)b |
| PASI 90 | 5 (2.9) | 241 (73.3)c | 166 (49.7)b | 6 (2.4) | 347 (70.0)c | 116 (46.8)b |
| PASI 100 | 1 (0.6) | 123 (37.4)a | 57 (17.1)d | 2 (0.8) | 169 (34.1)c | 51 (20.6)d |
| IGA 0/1 | 12 (6.9) | 280 (85.1)c | 220 (65.9)b | 21 (8.5) | 417 (84.1)c | 168 (67.7)b |
| IGA 0 | 2 (1.1) | 157 (47.7)a | 88 (26.3)d | 2 (0.8) | 215 (43.3)c | 71 (28.6)d |
| **Week 24** |                        |         |         |         |         |         |         |
| PASI 75 | - | 300 (91.2)a | 241 (72.2)c | - | 442 (89.1) | 176 (71.0)c |
| PASI 90 | - | 264 (80.2) | 177 (53.0)b | - | 373 (75.2) | 136 (54.8)b |
| PASI 100 | - | 146 (44.4) | 83 (24.9)e | - | 219 (44.2) | 66 (26.6)e |
| IGA 0/1 | - | 277 (84.2) | 206 (61.7)b | - | 414 (83.5) | 161 (64.9)b |
| IGA 0 | - | 173 (52.6) | 98 (29.3)b | - | 257 (51.8) | 78 (31.5)b |
| **Week 48** |                        |         |         |         |         |         |         |
| PASI 75 | - | 289 (87.8) | 209 (62.6)c | - | - | - |
| PASI 90 | - | 251 (76.3) | 160 (47.9)b | - | - | - |
| PASI 100 | - | 156 (47.4) | 78 (23.4)e | - | - | - |
| IGA 0/1 | - | 265 (80.5) | 185 (55.4)b | - | - | - |
| IGA 0 | - | 166 (50.5) | 86 (25.7)b | - | - | - |

a p < 0.001 for comparison between guselkumab and placebo.
b p < 0.001 for comparison between guselkumab and adalimumab for major secondary endpoints.
c p < 0.001 for the comparisons between guselkumab and placebo for the co-primary endpoints.
d comparisons between guselkumab and adalimumab were not performed.
e p < 0.001 for comparison between guselkumab and adalimumab.

**Response over time**
Guselkumab demonstrated rapid onset of efficacy, with a significantly higher percent improvement in PASI as compared with placebo as early as Week 2 (p < 0.001). The percentage of patients achieving a PASI 90 response was numerically higher for guselkumab than adalimumab starting at Week 8 with the difference reaching a maximum around Week 20 (VOYAGE 1 and 2) and maintained through Week 48 (VOYAGE 1) (see Figure 1).
In VOYAGE 1, for patients receiving continuous guselkumab treatment, the PASI 90 response rate was maintained from Week 52 through Week 252. For patients randomised to adalimumab at Week 0 who crossed over to guselkumab at Week 52, the PASI 90 response rate increased from Week 52 through Week 76 and was then maintained through Week 252 (see Figure 2).

The efficacy and safety of guselkumab was demonstrated regardless of age, gender, race, body weight, plaques location, PASI baseline severity, concurrent psoriatic arthritis, and previous treatment with a biologic therapy. Guselkumab was efficacious in conventional systemic-naive, biologic-naive, and biologic-exposed patients.
In VOYAGE 2, 88.6% of patients receiving guselkumab maintenance treatment at Week 48 were PASI 90 responders compared to 36.8% of patients who were withdrawn from treatment at Week 28 (p < 0.001). Loss of PASI 90 response was noted as early as 4 weeks after withdrawal of guselkumab treatment with a median time to loss of PASI 90 response of approximately 15 weeks. Among patients who were withdrawn from treatment and subsequently re-initiated guselkumab, 80% regained a PASI 90 response when assessed 20 weeks after initiation of retreatment.

In VOYAGE 2, among 112 patients randomised to adalimumab who failed to achieve a PASI 90 response at Week 28, 66% and 76% achieved a PASI 90 response after 20 and 44 weeks of treatment with guselkumab, respectively. In addition, among 95 patients randomised to guselkumab who failed to achieve a PASI 90 response at Week 28, 36% and 41% achieved a PASI 90 response with an additional 20 and 44 weeks of continued treatment with guselkumab, respectively. No new safety findings were observed in patients who switched from adalimumab to guselkumab.

Regional disease
In VOYAGE 1 and 2, significant improvements were seen in scalp, hand and foot, and nail psoriasis (as measured by the Scalp-specific Investigator Global Assessment [ss-IGA], Physician’s Global Assessment of Hands and/or Feet [hf-PGA], Fingernail Physician’s Global Assessment [f-PGA] and Nail Psoriasis Severity Index [NAPSI], respectively) in guselkumab treated patients compared to placebo treated patients at Week 16 (p < 0.001, Table 4). Guselkumab demonstrated superiority compared to adalimumab for scalp and hand and foot psoriasis at Week 24 (VOYAGE 1 and 2) and Week 48 (VOYAGE 1) (p ≤ 0.001, except for hand and foot psoriasis at Week 24 [VOYAGE 2] and Week 48 [VOYAGE 1], p < 0.05).

| Table 4: Summary of regional disease responses in VOYAGE 1 and VOYAGE 2 |
|-----------------------------|-----------------|----------------|-----------------|----------------|-----------------|----------------|
|                             | Placebo         | guselkumab     | adalimumab      | Placebo        | guselkumab     | adalimumab      |
| ss-IGA (N)a                  | 145             | 277            | 286             | 202            | 408            | 194            |
| ss-IGA 0/1b, n (%)           |                 |                |                 |                |                |                |
| Week 16                      | 21 (14.5)       | 231 (83.4)c    | 201 (70.3)d     | 22 (10.9)      | 329 (80.6)c    | 130 (67.0)d    |
| hf-PGA (N)a                  | 43              | 90             | 95              | 63             | 114            | 56             |
| hf-PGA 0/1b, n (%)           |                 |                |                 |                |                |                |
| Week 16                      | 6 (14.0)        | 66 (73.3)e     | 53 (55.8)d      | 9 (14.3)       | 88 (77.2)e     | 40 (71.4)d     |
| f-PGA (N)a                   | 88              | 174            | 173             | 123            | 246            | 124            |
| f-PGA 0/1, n (%)             |                 |                |                 |                |                |                |
| Week 16                      | 14 (15.9)       | 68 (39.1)e     | 88 (50.9)d      | 18 (14.6)      | 128 (52.0)e    | 74 (59.7)d     |
| NAPSI (N)a                   | 99              | 194            | 191             | 140            | 280            | 140            |
| Percent Improvement, mean (SD) | -0.9 (57.9) | 34.4 (42.4)f  | 38.0 (53.9)d | 1.8 (53.8) | 39.6 (45.6)c | 46.9 (48.1)d |

$\text{a}^\text{Includes only subjects with ss-IGA, f-PGA, hf-PGA score} \geq 2 \text{ at baseline or baseline NAPSI score} > 0.$

$\text{b}^\text{Includes only subjects achieving} \geq 2\text{-grade improvement from baseline in ss-IGA and/or hf-PGA.}$

$\text{c}^\text{p < 0.001 for comparison between guselkumab and placebo for the major secondary endpoint.}$

$\text{d}^\text{comparisons between guselkumab and adalimumab were not performed.}$

$\text{e}^\text{p < 0.001 for comparison between guselkumab and placebo.}$

Health-related quality of life / Patient reported outcomes
Across VOYAGE 1 and 2 significantly greater improvements in health-related quality of life as measured by Dermatology Life Quality Index (DLQI) and in patient-reported psoriasis symptoms (itching, pain, burning, stinging and skin tightness) and signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) as measured by the Psoriasis Symptoms and Signs Diary (PSSD) were observed in guselkumab patients compared to placebo patients at Week 16 (Table 5). Signs of improvement on patient-reported outcomes were maintained through Week 24 (VOYAGE 1).
and 2) and Week 48 (VOYAGE 1). In VOYAGE 1, for patients receiving continuous guselkumab treatment, these improvements were maintained in the open-label phase through Week 252 (Table 6).

Table 5: Summary of patient reported outcomes at week 16 in VOYAGE 1 and VOYAGE 2

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>VOYAGE 1 guselkumab</th>
<th>adalimumab</th>
<th>Placebo</th>
<th>VOYAGE 2 guselkumab</th>
<th>adalimumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>DLQI, subjects</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>with baseline score</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline,</td>
<td>-0.6</td>
<td>-11.2 (7.2)</td>
<td>-9.3 (7.8)</td>
<td>-2.6</td>
<td>-11.3 (6.8)</td>
<td>-9.7 (6.8)</td>
</tr>
<tr>
<td>mean (standard deviation)</td>
<td>(6.4)</td>
<td>(7.2)</td>
<td>(7.8)</td>
<td>(6.9)</td>
<td>(6.8)</td>
<td>(6.8)</td>
</tr>
<tr>
<td>PSSD Symptom</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>score, subjects</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>with baseline score</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptom score = 0, n</td>
<td>1</td>
<td>67 (27.0)</td>
<td>45 (16.5)</td>
<td>0</td>
<td>112 (27.3)</td>
<td>30 (15.0)</td>
</tr>
<tr>
<td>(%)</td>
<td>(0.8)</td>
<td>(27.0)</td>
<td>(16.5)</td>
<td>(0)</td>
<td>(27.3)</td>
<td>(15.0)</td>
</tr>
<tr>
<td>PSSD Sign score,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>subjects with baseline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>score &gt; 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sign score = 0, n</td>
<td>0</td>
<td>50 (20.2)</td>
<td>32 (11.7)</td>
<td>0</td>
<td>86 (20.9)</td>
<td>21 (10.4)</td>
</tr>
<tr>
<td>(%)</td>
<td>(0.8)</td>
<td>(20.2)</td>
<td>(11.7)</td>
<td>(0)</td>
<td>(20.9)</td>
<td>(10.4)</td>
</tr>
</tbody>
</table>

In VOYAGE 2, guselkumab patients had significantly greater improvement from baseline compared to placebo in health-related quality of life, anxiety and depression, and work limitation measures at Week 16, as measured by the 36-item Short Form (SF-36) health survey questionnaire, Hospital Anxiety and Depression Scale (HADS), and Work Limitations Questionnaire (WLQ), respectively. The improvements in SF-36, HADS and WLQ were all maintained through Week 48 and in the open-label phase through Week 252 among patients randomised to maintenance therapy at Week 28.

NAVIGATE

The NAVIGATE study examined the efficacy of guselkumab in patients who had an inadequate response (ie, who had not achieved a ‘cleared’ or ‘minimal’ response defined as IGA ≥ 2) to ustekinumab at Week 16. All patients (N=871) received open-label ustekinumab (45 mg ≤100 kg and
90 mg >100 kg) at Weeks 0 and 4. At Week 16, 268 patients with an IGA ≥ 2 score were randomised to either continue ustekinumab treatment (N=133) q12w, or to initiate guselkumab treatment (N=135) at Weeks 16, 20, and q8w thereafter. Baseline characteristics for randomised patients were similar to those observed in VOYAGE 1 and 2.

After randomisation, the primary endpoint was the number of post-randomisation visits between Weeks 12 and 24 at which patients achieved an IGA score 0/1 and had ≥ 2 grade improvement. Patients were examined at four week intervals for a total of four visits. Among patients who inadequately responded to ustekinumab at the time of randomisation, significantly greater improvement of efficacy was observed in patients who switched to guselkumab treatment compared to patients who continued ustekinumab treatment. Between 12 and 24 weeks after randomisation, guselkumab patients achieved an IGA score 0/1 with ≥ 2 grade improvement twice as often as ustekinumab patients (mean 1.5 vs 0.7 visits, respectively; p < 0.001). Additionally, at 12 weeks after randomisation a higher proportion of guselkumab patients compared to ustekinumab patients achieved an IGA score 0/1 and ≥ 2 grade improvement (31.1% vs. 14.3%, respectively; p = 0.001) and a PASI 90 response (48% vs 23%, respectively, p < 0.001). Differences in response rates between guselkumab and ustekinumab treated patients were noted as early as 4 weeks after randomisation (11.1% and 9.0%, respectively) and reached a maximum 24 weeks after randomisation (see Figure 3). No new safety findings were observed in patients who switched from ustekinumab to guselkumab.

**Figure 3:** Percent of subjects who achieved an IGA Score of cleared (0) or minimal (1) and at least a 2-grade improvement in IGA from week 0 through week 24 by visit after randomisation in NAVIGATE

![Figure 3](image)

**ECLIPSE**

Efficacy and safety of guselkumab were also investigated in a double-blind study compared to secukinumab. Patients were randomised to receive guselkumab (N=534; 100 mg at Week 0, 4 and q8w thereafter), or secukinumab (N=514; 300 mg at Week 0, 1, 2, 3, 4, and q4w thereafter). The last dose was at week 44 for both treatment groups.

Baseline disease characteristics were consistent with a population of moderate to severe plaque psoriasis with a median BSA of 20%, a median PASI score of 18, and an IGA score of severe for 24% of patients.
Guselkumab was superior to secukinumab as measured by the primary endpoint of PASI 90 response at Week 48 (84.5% versus 70.0%, p < 0.001). Comparative PASI response rates are presented in Table 7.

Table 7: PASI response rates in ECLIPSE

<table>
<thead>
<tr>
<th>Primary Endpoint</th>
<th>Number of patients (%)</th>
<th>Guselkumab (N=534)</th>
<th>Secukinumab (N=514)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PASI 90 response at Week 48</td>
<td></td>
<td>451 (84.5%) (^a)</td>
<td>360 (70.0%)</td>
</tr>
<tr>
<td>Major Secondary Endpoints</td>
<td></td>
<td>452 (84.6%) (^b)</td>
<td>412 (80.2%)</td>
</tr>
<tr>
<td>PASI 75 response at both Week 12 and Week 48</td>
<td></td>
<td>477 (89.3%) (^c)</td>
<td>471 (91.6%)</td>
</tr>
<tr>
<td>PASI 90 response at Week 12</td>
<td></td>
<td>369 (69.1%) (^c)</td>
<td>391 (76.1%)</td>
</tr>
<tr>
<td>PASI 100 response at Week 48</td>
<td></td>
<td>311 (58.2%) (^c)</td>
<td>249 (48.4%)</td>
</tr>
</tbody>
</table>

\(^a\) p < 0.001 for superiority
\(^b\) p < 0.001 for non-inferiority, p=0.062 for superiority
\(^c\) formal statistical testing was not performed

Guselkumab and secukinumab PASI 90 response rates through Week 48 are presented in Figure 4.

Figure 4: Percent of subjects who achieved a PASI 90 response through week 48 by visit (Subjects randomised at Week 0) in ECLIPSE

Psoriatic arthritis (PsA)
Guselkumab has been shown to improve signs and symptoms, physical function and health-related quality of life, and reduce the rate of progression of peripheral joint damage in adult patients with active PsA.

DISCOVER 1 and DISCOVER 2
Two randomised, double-blind, placebo-controlled Phase III studies (DISCOVER 1 and DISCOVER 2) evaluated the efficacy and safety of guselkumab versus placebo in adult patients with active PsA (≥ 3 swollen and ≥ 3 tender joints, and a C-reactive protein (CRP) level of ≥ 0.3 mg/dL in DISCOVER 1, and ≥ 5 swollen and ≥ 5 tender joints, and a CRP level of ≥ 0.6 mg/dL in...
DISCOVER 2), despite conventional synthetic (cs)DMARD, apremilast, or nonsteroidal anti-inflammatory drug (NSAID) therapy. Patients in these studies had a diagnosis of PsA based on the Classification criteria for Psoriatic Arthritis (CASPAR) for a median duration of 4 years. Patients with different subtypes of PsA were enrolled in both studies, including polyarticular arthritis with the absence of rheumatoid nodules (40%), spondylitis with peripheral arthritis (30%), asymmetric peripheral arthritis (23%), distal interphalangeal involvement (7%) and arthritis mutilans (1%). Over 65% and 42% of the patients had enthesitis and dactylitis at baseline, respectively, and over 75% of patients had ≥ 3% BSA psoriasis skin involvement. DISCOVER 1 and DISCOVER 2 evaluated 381 and 739 patients, respectively, who received treatment with guselkumab 100 mg administered at Weeks 0 and 4 followed by every 8 weeks (q8w) or guselkumab 100 mg q4w, or placebo. At Week 24, placebo subjects in both studies crossed over to receive guselkumab 100 mg q4w. Approximately 58% of patients in both studies continued on stable doses of MTX (≤ 25 mg/week).

In both studies over 90% of patients had prior csDMARD use. In DISCOVER 1, 31% of patients had previously received anti-TNFα treatment. In DISCOVER 2, all patients were naive to biologic therapy.

**Signs and symptoms**

Treatment with guselkumab resulted in significant improvements in the measures of disease activity compared to placebo at Week 24. The primary endpoint in both studies was the percentage of patients who achieved American College of Rheumatology (ACR) 20 response at Week 24. The key efficacy results are shown in Table 8.
Table 8: Clinical responses in DISCOVER 1 and DISCOVER 2

<table>
<thead>
<tr>
<th></th>
<th>DISCOVER 1</th>
<th>DISCOVER 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo (N=126)</td>
<td>guselkumab 100 mg q8w (N=127)</td>
</tr>
<tr>
<td><strong>ACR 20 response</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 16</td>
<td>25.4%</td>
<td>52.0%</td>
</tr>
<tr>
<td>Difference from placebo</td>
<td>-</td>
<td>26.7%</td>
</tr>
<tr>
<td>(95% CI)</td>
<td></td>
<td>(15.3, 38.1)</td>
</tr>
<tr>
<td>Week 24</td>
<td>22.2%</td>
<td>52.0%</td>
</tr>
<tr>
<td>Difference from placebo</td>
<td>-</td>
<td>29.8%</td>
</tr>
<tr>
<td>(95% CI)</td>
<td></td>
<td>(18.6, 41.1)</td>
</tr>
<tr>
<td><strong>ACR 50 response</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 16</td>
<td>12.7%</td>
<td>22.8%</td>
</tr>
<tr>
<td>Difference from placebo</td>
<td>-</td>
<td>10.2%</td>
</tr>
<tr>
<td>(95% CI)</td>
<td></td>
<td>(1.0, 19.3)</td>
</tr>
<tr>
<td>Week 24</td>
<td>8.7%</td>
<td>29.9%</td>
</tr>
<tr>
<td>Difference from placebo</td>
<td>-</td>
<td>21.4%</td>
</tr>
<tr>
<td>(95% CI)</td>
<td></td>
<td>(12.1, 30.7)</td>
</tr>
<tr>
<td><strong>ACR 70 response</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 24</td>
<td>5.6%</td>
<td>11.8%</td>
</tr>
<tr>
<td>Difference from placebo</td>
<td>-</td>
<td>6.4%</td>
</tr>
<tr>
<td>(95% CI)</td>
<td></td>
<td>(-0.3, 13.1)</td>
</tr>
<tr>
<td><strong>DAS 28 (CRP) LSMean change from baseline</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 24</td>
<td>-0.70</td>
<td>-1.43</td>
</tr>
<tr>
<td>Difference from placebo</td>
<td>-</td>
<td>-0.73</td>
</tr>
<tr>
<td>(95% CI)</td>
<td></td>
<td>(-0.98, -0.48)</td>
</tr>
<tr>
<td><strong>Minimal Disease Activity (MDA)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 24</td>
<td>11.1%</td>
<td>22.8%</td>
</tr>
<tr>
<td>Difference from placebo</td>
<td>-</td>
<td>11.9%</td>
</tr>
<tr>
<td>(95% CI)</td>
<td></td>
<td>(2.9, 20.9)</td>
</tr>
<tr>
<td><strong>Patients with ≥ 3% BSA and IGA ≥ 2</strong></td>
<td>n=78</td>
<td>n=82</td>
</tr>
<tr>
<td><strong>IGA response</strong> h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 24</td>
<td>15.4%</td>
<td>57.3%</td>
</tr>
<tr>
<td>Difference from placebo</td>
<td>-</td>
<td>42.0%</td>
</tr>
<tr>
<td>(95% CI)</td>
<td></td>
<td>(28.9, 55.1)</td>
</tr>
<tr>
<td><strong>PASI 90 response</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 16</td>
<td>10.3%</td>
<td>45.1%</td>
</tr>
<tr>
<td>Difference from placebo</td>
<td>-</td>
<td>34.9%</td>
</tr>
<tr>
<td>(95% CI)</td>
<td></td>
<td>(22.2, 47.6)</td>
</tr>
<tr>
<td>Week 24</td>
<td>11.5%</td>
<td>50.0%</td>
</tr>
<tr>
<td>Difference from placebo</td>
<td>-</td>
<td>38.6%</td>
</tr>
<tr>
<td>(95% CI)</td>
<td></td>
<td>(25.8, 51.4)</td>
</tr>
</tbody>
</table>
Clinical response was maintained up to Week 52 as assessed by ACR 20/50/70, DAS 28 (CRP), MDA, IGA and PASI 90 response rates in DISCOVER 1 and DISCOVER 2 (see Table 9).

<table>
<thead>
<tr>
<th>Table 9: Clinical responses in DISCOVER 1 and DISCOVER 2 at week 52a</th>
</tr>
</thead>
<tbody>
<tr>
<td>DISCOVER 1</td>
</tr>
<tr>
<td>guselkumab 100 mg q8w</td>
</tr>
<tr>
<td>ACR 20</td>
</tr>
<tr>
<td>Nb</td>
</tr>
<tr>
<td>% Response</td>
</tr>
<tr>
<td>ACR 50</td>
</tr>
<tr>
<td>Nb</td>
</tr>
<tr>
<td>% Response</td>
</tr>
<tr>
<td>ACR 70</td>
</tr>
<tr>
<td>Nb</td>
</tr>
<tr>
<td>% Response</td>
</tr>
<tr>
<td>DAS 28 (CRP) change from baseline</td>
</tr>
<tr>
<td>Mean (SD)</td>
</tr>
<tr>
<td>MDA</td>
</tr>
<tr>
<td>Nb</td>
</tr>
<tr>
<td>% Response</td>
</tr>
<tr>
<td>Patients with ≥ 3% BSA and IGA ≥ 2 at baseline</td>
</tr>
<tr>
<td>IGA Response</td>
</tr>
<tr>
<td>Nb</td>
</tr>
<tr>
<td>% Response</td>
</tr>
<tr>
<td>PASI 90</td>
</tr>
<tr>
<td>Nb</td>
</tr>
<tr>
<td>% Response</td>
</tr>
</tbody>
</table>

'a There was no placebo arm beyond Week 24.
b Evaluative subjects with an observed response status.
c Subjects have an observed change from baseline.
Table 10: Clinical responses in DISCOVER 2 at week 100a

<table>
<thead>
<tr>
<th></th>
<th>guselkumab 100 mg q8w</th>
<th>guselkumab 100 mg q4w</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACR 20</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N(^b)</td>
<td>223</td>
<td>219</td>
</tr>
<tr>
<td>% Response</td>
<td>82.1%</td>
<td>84.9%</td>
</tr>
<tr>
<td><strong>ACR 50</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N(^b)</td>
<td>224</td>
<td>220</td>
</tr>
<tr>
<td>% Response</td>
<td>60.7%</td>
<td>62.3%</td>
</tr>
<tr>
<td><strong>ACR 70</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N(^b)</td>
<td>224</td>
<td>220</td>
</tr>
<tr>
<td>% Response</td>
<td>39.3%</td>
<td>38.6%</td>
</tr>
<tr>
<td><strong>DAS 28 (CRP) change from baseline</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N(^c)</td>
<td>223</td>
<td>219</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>-2.37 (1.215)</td>
<td>-2.36 (1.120)</td>
</tr>
<tr>
<td><strong>MDA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N(^b)</td>
<td>224</td>
<td>220</td>
</tr>
<tr>
<td>% Response</td>
<td>44.6%</td>
<td>42.7%</td>
</tr>
<tr>
<td><strong>Patients with (\geq 3%) BSA and IGA (\geq 2) at baseline</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IGA Response</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N(^b)</td>
<td>165</td>
<td>170</td>
</tr>
<tr>
<td>% Response</td>
<td>76.4%</td>
<td>82.4%</td>
</tr>
<tr>
<td><strong>PASI 90</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N(^b)</td>
<td>164</td>
<td>170</td>
</tr>
<tr>
<td>% Response</td>
<td>75.0%</td>
<td>80.0%</td>
</tr>
</tbody>
</table>

\(^a\) There was no placebo arm beyond Week 24.
\(^b\) Evaluable subjects with an observed response status.
\(^c\) Subjects have an observed change from baseline.

Response over time
In DISCOVER 2, a greater ACR 20 response was observed in both guselkumab groups compared to placebo as early as Week 4 and the treatment difference continued to increase over time through Week 24 (Figure 5).

Figure 5: ACR 20 response by visit through week 24 in DISCOVER 2

In DISCOVER 2, for subjects receiving continuous guselkumab treatment at week 24, ACR 20
response was maintained from Week 24 to Week 52 (see Figure 6). For subjects receiving continuous guselkumab treatment at week 52, ACR 20 response was maintained from Week 52 to Week 100 (see Figure 7).

Responses observed in the guselkumab groups were similar regardless of concomitant csDMARD use, including MTX (DISCOVER 1 and 2). Additionally, examination of age, gender, race, body weight, and previous csDMARD use (DISCOVER 1 and 2) and previous anti-TNFα use (DISCOVER 1), did not identify differences in response to guselkumab among these subgroups.

In DISCOVER 1 and 2, improvements were shown in all components of the ACR scores including patient assessment of pain. At Week 24 in both studies, the proportion of patients achieving a modified PsA response criteria (PsARC) response was greater in the guselkumab groups compared to placebo. PsARC responses were maintained from Week 24 to Week 52 in DISCOVER 1 and Week 100 in DISCOVER 2.

Dactylitis and enthesitis were assessed based on pooled data from DISCOVER 1 and 2. At Week 24, among patients with dactylitis at baseline, the proportion of subjects with dactylitis resolution was greater in the guselkumab q8w group (59.4%, nominal p < 0.001) and q4w group (63.5%, p = 0.006) compared to placebo (42.2%). At Week 24, among patients with enthesitis at baseline, the proportion of subjects with enthesitis resolution was greater in the guselkumab q8w group (49.6%, nominal p < 0.001) and q4w group (44.9%, p = 0.006) compared to placebo (29.4%). At Week 52, the proportions of subjects with dactylitis resolution (81.2% in q8w group and 80.4% in q4w group) and enthesitis resolution (62.7% in q8w group and 60.9% in q4w group) were maintained. In DISCOVER 2, among subjects with dactylitis and enthesitis at baseline, the proportion of patients with dactylitis resolution (91.1% in q8w group and 82.9% in q4w group) and enthesitis resolution (77.5% in q8w group and 67.7% in q4w group) were maintained at Week 100.

In DISCOVER 1 and 2, patients treated with guselkumab who had spondylitis with peripheral arthritis as their primary presentation, demonstrated greater improvement from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) compared to placebo at Week 24. Improvement in BASDAI was maintained from Week 24 to Week 52 in DISCOVER 1 and Week 100 in DISCOVER 2.

**Radiographic response**

In DISCOVER 2, inhibition of structural damage progression was measured radiographically and expressed as the mean change from baseline in the total modified van der Heijde-Sharp (vdH-S) score. At Week 24, the guselkumab q4w group demonstrated statistically significantly less radiographic progression and the guselkumab q8w group showed numerically less progression than placebo (Table 11). The observed benefit with the guselkumab q4w dosing regimen on inhibition of radiographic progression (ie, smaller mean change from baseline in total modified vdH-S score in the q4w group versus placebo) was most pronounced in subjects with both a high C-reactive protein value and high number of joints with erosions at baseline.
Table 11: Change from baseline in total modified vdH-S score at week 24 in DISCOVER 2

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>LSMean changec (95% CI) from baseline in modified vdH-S score at Week 24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>246</td>
<td>0.95 (0.61, 1.29)</td>
</tr>
<tr>
<td>Guselkumab 100 mg q8w</td>
<td>248</td>
<td>0.52a (0.18, 0.86)</td>
</tr>
<tr>
<td>Guselkumab 100 mg q4w</td>
<td>245</td>
<td>0.29b (-0.05, 0.63)</td>
</tr>
</tbody>
</table>

a not statistically significant p = 0.068 (major secondary endpoint)
b p = 0.006 (major secondary endpoint)
c LSmean change = least squares mean change
d CI = confidence interval

At Week 52 and Week 100, the mean change from baseline in total modified vdH-S was similar in the guselkumab q8w and q4w groups (Table 12).

Table 12: Change from baseline in total modified vdH-S score at week 52 and week 100 in DISCOVER 2

<table>
<thead>
<tr>
<th></th>
<th>Na</th>
<th>Mean change (SD)b from baseline in total modified vdH-S score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week 52</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guselkumab 100 mg q8w</td>
<td>235</td>
<td>0.97 (3.623)</td>
</tr>
<tr>
<td>Guselkumab 100 mg q4w</td>
<td>229</td>
<td>1.07 (3.843)</td>
</tr>
<tr>
<td>Week 100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guselkumab 100 mg q8w</td>
<td>216</td>
<td>1.50 (4.393)</td>
</tr>
<tr>
<td>Guselkumab 100 mg q4w</td>
<td>211</td>
<td>1.68 (7.018)</td>
</tr>
</tbody>
</table>

a Evaluable subjects have observed change for the specified time period
b SD = standard deviation

Note: no placebo group beyond Week 24

Physical function and health-related quality of life

In DISCOVER 1 and 2, guselkumab treated patients showed significant improvement (p < 0.001) in physical function compared to placebo as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24. Improvements in HAQ-DI were maintained from Week 24 to Week 52 in DISCOVER 1 and Week 100 in DISCOVER 2.

A significantly greater improvement from baseline in the SF-36 Physical Component Summary (PCS) score was observed in guselkumab treated patients compared to placebo at Week 24 in DISCOVER 1 (p < 0.001 for both dose groups) and DISCOVER 2 (p = 0.006 for q4w group). At Week 24, a greater increase from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score was observed in guselkumab treated patients compared to placebo in both studies. In DISCOVER 2, greater improvements in health-related quality of life as measured by the Dermatology Life Quality Index (DLQI) were observed in guselkumab treated patients compared to placebo at Week 24. Improvements in SF-36 PCS, FACIT-F and DLQI scores were maintained from Week 24 to Week 52 in DISCOVER 1 and Week 100 in DISCOVER 2.

Paediatric population

The European Medicines Agency has deferred the obligation to submit the results of studies with guselkumab in one or more subsets of the paediatric population in plaque psoriasis and psoriatic arthritis (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

Absorption

Following a single 100 mg subcutaneous injection in healthy subjects, guselkumab reached a mean (± SD) maximum serum concentration (Cmax) of 8.09 ± 3.68 mcg/mL by approximately 5.5 days post dose.
Steady-state serum guselkumab concentrations were achieved by Week 20 following subcutaneous administrations of 100 mg guselkumab at Weeks 0 and 4, and every 8 weeks thereafter. The mean (± SD) steady-state trough serum guselkumab concentrations in two Phase III studies in patients with plaque psoriasis were 1.15 ± 0.73 mcg/mL and 1.23 ± 0.84 mcg/mL. The pharmacokinetics of guselkumab in subjects with psoriatic arthritis was similar to that in subjects with psoriasis. Following subcutaneous administration of 100 mg of guselkumab at Weeks 0, 4, and every 8 weeks thereafter, mean steady-state trough serum guselkumab concentration was also approximately 1.2 mcg/mL. Following subcutaneous administration of 100 mg of guselkumab every 4 weeks, mean steady-state trough serum guselkumab concentration was approximately 3.8 mcg/mL.

The absolute bioavailability of guselkumab following a single 100 mg subcutaneous injection was estimated to be approximately 49% in healthy subjects.

**Distribution**

Mean volume of distribution during the terminal phase ($V_z$) following a single intravenous administration to healthy subjects ranged from approximately 7 to 10 L across studies.

**Biotransformation**

The exact pathway through which guselkumab is metabolised has not been characterised. As a human IgG mAb, guselkumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.

**Elimination**

Mean systemic clearance (CL) following a single intravenous administration to healthy subjects ranged from 0.288 to 0.479 L/day across studies. Mean half-life ($T_{1/2}$) of guselkumab was approximately 17 days in healthy subjects and approximately 15 to 18 days in patients with plaque psoriasis across studies.

Population pharmacokinetic analyses indicated that concomitant use of NSAIDs, oral corticosteroids and csDMARDs such as methotrexate, did not affect the clearance of guselkumab.

**Linearity/non-linearity**

The systemic exposure of guselkumab ($C_{max}$ and AUC) increased in an approximately dose-proportional manner following a single subcutaneous injection at doses ranging from 10 mg to 300 mg in healthy subjects or patients with plaque psoriasis.

**Elderly patients**

No specific studies have been conducted in elderly patients. Of the 1384 plaque psoriasis patients exposed to guselkumab in Phase III clinical studies and included in the population pharmacokinetic analysis, 70 patients were 65 years of age or older, including 4 patients who were 75 years of age or older. Of the 746 psoriatic arthritis patients exposed to guselkumab in Phase III clinical studies, a total of 38 patients were 65 years of age or older, and no patients were 75 years of age or older.

Population pharmacokinetic analyses in plaque psoriasis and psoriatic arthritis patients indicated no apparent changes in CL/F estimate in patients ≥ 65 years of age compared to patients < 65 years of age, suggesting no dose adjustment is needed for elderly patients.

**Patients with renal or hepatic impairment**

No specific study has been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of guselkumab. Renal elimination of intact guselkumab, an IgG mAb, is expected to
be low and of minor importance; similarly, hepatic impairment is not expected to influence clearance of guselkumab as IgG mAbs are mainly eliminated via intracellular catabolism.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeat-dose toxicity, toxicity to reproduction and pre- and post-natal development.

In repeat-dose toxicity studies in cynomolgus monkeys, guselkumab was well tolerated via intravenous and subcutaneous routes of administration. A weekly subcutaneous dose of 50 mg/kg to monkeys resulted in exposure (AUC) and C\text{max} values that were at least 49-fold and >200-fold higher, respectively, than those measured in the human clinical PK study. Additionally, there were no adverse immunotoxicity or cardiovascular safety pharmacology effects noted during the conduct of the repeat-dose toxicity studies or in a targeted cardiovascular safety pharmacology study in cynomolgus monkeys.

There were no preneoplastic changes observed in histopathology evaluations of animals treated up to 24-weeks, or following the 12-week recovery period during which active substance was detectable in the serum.

No mutagenicity or carcinogenicity studies were conducted with guselkumab.

Guselkumab could not be detected in breast milk from cynomolgus monkeys as measured at post-natal day 28.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Histidine
Histidine monohydrochloride monohydrate
Polysorbate 80
Sucrose
Water for injections

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

2 years.

6.4 Special precautions for storage

Store in a refrigerator (2°C–8°C). Do not freeze.
Keep the pre-filled syringe or pre-filled pen in the outer carton in order to protect from light.

6.5 Nature and contents of container

Tremfya 100 mg solution for injection in pre-filled syringe

1 mL solution in a pre-filled glass syringe with a fixed needle and a needle shield, assembled in an automatic needle guard.
Tremfya is available in packs containing one pre-filled syringe and in multipacks containing 2 (2 packs of 1) pre-filled syringes.

Not all pack sizes may be marketed.

**Tremfya 100 mg solution for injection in pre-filled pen**

1 mL solution in a pre-filled glass syringe assembled in a pre-filled pen with an automatic needle guard.

Tremfya is available in a pack containing one pre-filled pen and in a multipack containing 2 (2 packs of 1) pre-filled pens.

Not all pack sizes may be marketed.

**6.6 Special precautions for disposal and other handling**

After removing the pre-filled syringe or pre-filled pen from the refrigerator, keep the pre-filled syringe or pre-filled pen inside the carton and allow to reach room temperature by waiting for 30 minutes before injecting Tremfya. The pre-filled syringe or pre-filled pen should not be shaken.

Prior to use, a visual inspection of the pre-filled syringe or pre-filled pen is recommended. The solution should be clear, colourless to light yellow, and may contain a few small white or clear particles. Tremfya should not be used if the solution is cloudy or discoloured, or contains large particles.

Each pack is provided with an ‘Instructions for use’ leaflet that fully describes the preparation and administration of the pre-filled syringe or pre-filled pen.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**7. MARKETING AUTHORISATION HOLDER**

Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium

**8. MARKETING AUTHORISATION NUMBER(S)**

EU/1/17/1234/001 1 pre-filled syringe
EU/1/17/1234/002 1 pre-filled pen
EU/1/17/1234/003 2 pre-filled pens
EU/1/17/1234/004 2 pre-filled syringes

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 10 November 2017
Date of latest renewal:
10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/
ANNEX II

A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturers of the biological active substance

Biogen Inc. (BIIB)
5000 Davis Drive
Research Triangle Park
NC27709
USA

Janssen Sciences Ireland UC
Barnahely
Ringaskiddy
Co. Cork
Ireland

Name and address of the manufacturer responsible for batch release

Janssen Biologics B.V.
Einsteinweg 101
2333CB Leiden
The Netherlands

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder (MAH) shall submit the first PSUR for this product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
- At the request of the European Medicines Agency;
Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

Tremfya 100 mg solution for injection in pre-filled syringe
guselkumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled syringe contains 100 mg of guselkumab in 1 mL.

3. LIST OF EXCIPIENTS

Excipients: sucrose, histidine, histidine monohydrochloride monohydrate, polysorbate 80, water for injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection

1 pre-filled syringe

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Subcutaneous use
Read the package leaflet before use.
Do not shake.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.
Do not freeze.
Keep the pre-filled syringe in the outer carton in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/17/1234/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Tremfya 100 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON FOR MULTIPACK (INCLUDING BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Tremfya 100 mg solution for injection in pre-filled syringe
guselkumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled syringe contains 100 mg of guselkumab in 1 mL.

3. LIST OF EXCIPIENTS

Excipients: sucrose, histidine, histidine monohydrochloride monohydrate, polysorbate 80, water for injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection

Multipack: 2 (2 packs of 1) pre-filled syringes

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Subcutaneous use
Read the package leaflet before use.
Do not shake.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.
Do not freeze.

Keep the pre-filled syringe in the outer carton in order to protect from light.
10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Janssen-Cilag International NV  
Turnhoutseweg 30  
B-2340 Beerse  
Belgium

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/17/1234/004 (2 packs, each containing 1 pre-filled syringe)

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Tremfya 100 mg

17. **UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC  
SN  
NN
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Tremfya 100 mg solution for injection in pre-filled syringe
guselkumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled syringe contains 100 mg of guselkumab in 1 mL.

3. LIST OF EXCIPIENTS

Excipients: sucrose, histidine, histidine monohydrochloride monohydrate, polysorbate 80, water for injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection

1 pre-filled syringe
Component of a multipack, cannot be sold separately

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Subcutaneous use
Read the package leaflet before use.
Do not shake.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.
Do not freeze.
Keep the pre-filled syringe in the outer carton in order to protect from light.

| 10. | SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE |
| 11. | NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER |
| Janssen-Cilag International NV |
| Turnhoutseweg 30 |
| B-2340 Beerse |
| Belgium |
| 12. | MARKETING AUTHORISATION NUMBER(S) |
| EU/1/17/1234/004 |
| 13. | BATCH NUMBER |
| Lot |
| 14. | GENERAL CLASSIFICATION FOR SUPPLY |
| 15. | INSTRUCTIONS ON USE |
| 16. | INFORMATION IN BRAILLE |
| Tremfya 100 mg |
| 17. | UNIQUE IDENTIFIER – 2D BARCODE |
| 18. | UNIQUE IDENTIFIER - HUMAN READABLE DATA |
**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**PRE-FILLED SYRINGE LABEL**

1. **NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION**

   Tremfya 100 mg injection  
guselkumab  
SC

2. **METHOD OF ADMINISTRATION**

3. **EXPIRY DATE**

   EXP

4. **BATCH NUMBER**

   Lot

5. **CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT**

   1 mL

6. **OTHER**
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

Tremfya 100 mg solution for injection in pre-filled pen
guselkumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled pen contains 100 mg of guselkumab in 1 mL.

3. LIST OF EXCIPIENTS

Excipients: sucrose, histidine, histidine monohydrochloride monohydrate, polysorbate 80, water for injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection

1 pre-filled pen

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Do not shake
Subcutaneous use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.
Do not freeze.
Keep the pre-filled pen in the outer carton in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORIZATION HOLDER

Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium

12. MARKETING AUTHORIZATION NUMBER(S)

EU/1/17/1234/002

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Tremfya 100 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Tremfya 100 mg solution for injection in pre-filled pen
guselkumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled pen contains 100 mg of guselkumab in 1 mL.

3. LIST OF EXCIPIENTS

Excipients: sucrose, histidine, histidine monohydrochloride monohydrate, polysorbate 80, water for
injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection

1 pre-filled pen
Component of a multipack, cannot be sold separately

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Do not shake
Subcutaneous use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.
Do not freeze.
Keep the pre-filled pen in the outer carton in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/17/1234/003

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Tremfya 100 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER CARTON FOR MULTIPACK (INCLUDING BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Tremfya 100 mg solution for injection in pre-filled pen
guselkumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled pen contains 100 mg of guselkumab in 1 mL.

3. LIST OF EXCIPIENTS

Excipients: sucrose, histidine, histidine monohydrochloride monohydrate, polysorbate 80, water for
injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection

Multipack: 2 (2 packs of 1) pre-filled pens

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Do not shake
Subcutaneous use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.
Do not freeze.
Keep the pre-filled pen in the outer carton in order to protect from light.

### 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

### 11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Janssen-Cilag International NV  
Turnhoutseweg 30  
B-2340 Beerse  
Belgium

### 12. MARKETING AUTHORISATION NUMBER(S)

EU/1/17/1234/003 (2 packs, each containing 1 pre-filled pen)

### 13. BATCH NUMBER

Lot

### 14. GENERAL CLASSIFICATION FOR SUPPLY

### 15. INSTRUCTIONS ON USE

### 16. INFORMATION IN BRAILLE

Tremfya 100 mg

### 17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

### 18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC  
SN  
NN
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
PRE-FILLED PEN LABEL

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Tremfya 100 mg injection
guselkumab
SC

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

1 mL

6. OTHER
B. PACKAGE LEAFLET
What is in this leaflet

1. What Tremfya is and what it is used for
2. What you need to know before you use Tremfya
3. How to use Tremfya
4. Possible side effects
5. How to store Tremfya
6. Contents of the pack and other information

1. What Tremfya is and what it is used for

Tremfya contains the active substance guselkumab which is a type of protein called a monoclonal antibody.

This medicine works by blocking the activity of a protein called IL-23, which is present at increased levels in people with psoriasis and psoriatic arthritis.

Plaque psoriasis
Tremfya is used to treat adults with moderate to severe “plaque psoriasis”, an inflammatory condition affecting the skin and nails.

Tremfya can improve the condition of the skin and appearance of nails and reduce symptoms, such as scaling, shedding, flaking, itching, pain and burning.

Psoriatic arthritis
Tremfya is used to treat a condition called “psoriatic arthritis”, an inflammatory disease of the joints, often accompanied by plaque psoriasis. If you have psoriatic arthritis you will first be given other medicines. If you do not respond well enough to these medicines or in case of intolerance, you will be given Tremfya to reduce the signs and symptoms of the disease. Tremfya can be used alone or with another medicine named methotrexate.

Using Tremfya in psoriatic arthritis will benefit you by reducing the signs and symptoms of the disease, slowing down the damage to the cartilage and bone of the joints and improving your ability to do normal daily activities.
2. What you need to know before you use Tremfya

Do not use Tremfya
- if you are allergic to guselkumab or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice before using Tremfya.
- if you have an active infection, including active tuberculosis.

Warnings and precautions
Talk to your doctor, pharmacist or nurse before using Tremfya:
- if you are being treated for an infection;
- if you have an infection that does not go away or that keeps coming back;
- if you have tuberculosis or have been in close contact with someone with tuberculosis;
- if you think you have an infection or have symptoms of an infection (see below under ‘Look out for infections and allergic reactions’);
- if you have recently had a vaccination or if you are due to have a vaccination during treatment with Tremfya.

If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before using Tremfya.

As directed by your doctor, you may need blood tests to check if you have high levels of liver enzymes before you start taking Tremfya and when using it. Increases in liver enzymes may occur more frequently in patients receiving Tremfya every 4 weeks than in patients receiving Tremfya every 8 weeks (see “How to use Tremfya” in section 3).

Look out for infections and allergic reactions
Tremfya can potentially cause serious side effects, including allergic reactions and infections. You must look out for signs of these conditions while you are taking Tremfya.

Signs of infections may include fever or flu like symptoms; muscle aches; cough; shortness of breath; burning when you urinate or urinating more often than usual; blood in your phlegm (mucus); weight loss; diarrhoea or stomach pain; warm, red, or painful skin or sores on your body which are different from your psoriasis.

Serious allergic reactions, which can include the following symptoms, swollen face, lips, mouth, tongue or throat, difficulty swallowing or breathing and hives, have occurred with Tremfya (see “Serious side effects” in section 4).

Stop using Tremfya and tell your doctor or seek medical help immediately if you notice any signs indicating a possible serious allergic reaction or an infection.

Children and adolescents
Tremfya is not recommended for children and adolescents under 18 years of age because it has not been studied in this age group.

Other medicines and Tremfya
Tell your doctor or pharmacist:
- if you are using, have recently used or might use any other medicines.
- if you recently had or are due to have a vaccination. You should not be given certain types of vaccines (live vaccines) while using Tremfya.

Pregnancy and breast-feeding
- Tremfya should not be used in pregnancy as the effects of this medicine in pregnant women are not known. If you are a woman of childbearing potential, you are advised to avoid becoming pregnant and must use adequate contraception while using Tremfya and for at least 12 weeks
after the last Tremfya dose. Talk to your doctor if you are pregnant, think you may be pregnant or are planning to have a baby.

- Talk to your doctor if you are breast-feeding or are planning to breast-feed. You and your doctor should decide if you will breast-feed or use Tremfya.

**Driving and using machines**
Tremfya is unlikely to influence your ability to drive and use machines.

### 3. How to use Tremfya

Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

**How much Tremfya is given and for how long**
Your doctor will decide for how long you need to use Tremfya.

**Plaque psoriasis**
- The dose is 100 mg (the content of 1 pre-filled syringe) given by injection under the skin (subcutaneous injection). This may be given by your doctor or nurse.
- After the first dose, you will have the next dose 4 weeks later, and then every 8 weeks.

**Psoriatic arthritis**
- The dose is 100 mg (the content of 1 pre-filled syringe) given by injection under the skin (subcutaneous injection). This may be given by your doctor or nurse.
- After the first dose, you will receive the next dose 4 weeks later, and then every 8 weeks. For some patients, after the first dose, Tremfya may be given every 4 weeks. Your doctor will decide how often you may receive Tremfya.

At the start, your doctor or nurse will inject Tremfya. However, you may decide together with your doctor to give Tremfya yourself in which case you will get the appropriate training on how to inject Tremfya. Talk to your doctor or nurse if you have any questions about giving yourself an injection. It is important not to try to inject yourself until you have been trained by your doctor or nurse.

For detailed instructions on how to use Tremfya, carefully read the ‘Instructions for use’ leaflet before use, which is included in the carton.

**If you use more Tremfya than you should**
If you have received more Tremfya than you should or the dose has been given sooner than prescribed, inform your doctor.

**If you forget to use Tremfya**
If you have forgotten to inject a dose of Tremfya, inform your doctor.

**If you stop using Tremfya**
You should not stop using Tremfya without speaking to your doctor first. If you stop treatment, your symptoms may come back.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

### 4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

**Serious side effects**
Tell your doctor or seek medical help immediately if you get any of the following side effects:
Possible serious allergic reaction (may affect up to 1 in 100 people) - the signs may include:
- difficulty breathing or swallowing
- swelling of the face, lips, tongue or throat
- severe itching of the skin, with a red rash or raised bumps

Other side effects
The following side effects are all mild to moderate. If any of these side effects becomes severe, tell your doctor, pharmacist or nurse immediately.

Very common (may affect more than 1 in 10 people)
- respiratory tract infections

Common (may affect up to 1 in 10 people)
- headache
- joint pain (arthralgia)
- diarrhoea
- redness, irritation or pain at the injection site
- increased level of liver enzymes in the blood

Uncommon (may affect up to 1 in 100 people)
- allergic reaction
- skin rash
- decreased number of a type of white blood cell called neutrophils
- herpes simplex infections
- fungal infection of the skin, for instance between the toes (e.g., athlete’s foot)
- stomach flu (gastroenteritis)
- hives

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Tremfya

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the syringe label and on the outer carton after “EXP”. The expiry date refers to the last day of that month.

Keep the pre-filled syringe in the outer carton in order to protect from light.

Store in a refrigerator (2°C–8°C). Do not freeze.

Do not shake.

Do not use this medicine if you notice that the medicine is cloudy or discoloured, or contains large particles. Before use, remove the carton from the refrigerator and keep the pre-filled syringe inside the carton and allow to reach room temperature by waiting for 30 minutes.

This medicine is for single use only. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information

What Tremfya contains
- The active substance is guselkumab. Each pre-filled syringe contains 100 mg of guselkumab in 1 mL solution.
- The other ingredients are histidine, histidine monohydrochloride monohydrate, polysorbate 80, sucrose and water for injections.

What Tremfya looks like and contents of the pack
Tremfya is a clear, colourless to light yellow solution for injection (injection). It is available in packs containing one pre-filled syringe and in multipacks comprising 2 cartons, each containing 1 pre-filled syringe. Not all pack sizes may be marketed.

Marketing Authorisation Holder
Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium

Manufacturer
Janssen Biologics B.V.
Einsteinweg 101
2333CB Leiden
The Netherlands

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien
Janssen-Cilag NV
Tel/Tél: +32 14 64 94 11
janssen@jacbe.jnj.com

Lietuva
UAB "JOHNSON & JOHNSON"
Tel: +370 5 278 68 88
lt@its.jnj.com

България
„Джонсън & Джонсън България” ЕООД
Tel.: +359 2 489 94 00
jjsafety@its.jnj.com

Magyarország
Janssen-Cilag Kft.
Tel.: +36 1 884 2858
janssenhu@its.jnj.com

Luxembourg/Luxemburg
Janssen-Cilag NV
Tel/Tél: +32 14 64 94 11
janssen@jacbe.jnj.com

Česká republika
Janssen-Cilag s.r.o.
Tel.: +420 227 012 227

Malta
AM MANGION LTD.
Tel: +356 2397 6000

Danmark
Janssen-Cilag A/S
Tlf: +45 45 94 8282
jacdk@its.jnj.com

Nederland
Janssen-Cilag B.V.
Tel: +31 76 711 1111
janssen@jacnl.jnj.com
This leaflet was last revised in

Detailed information on this medicine is available on the European Medicines Agency web site:
Instructions for use
Tremfya
Pre-filled syringe

Important
If your doctor decides that you or a caregiver may be able to give your injections of Tremfya at home, you should receive training on the right way to prepare and inject Tremfya using the pre-filled syringe before attempting to inject.

Please read these Instructions for use before using the Tremfya pre-filled syringe and each time you get a refill. There may be new information. This instruction guide does not take the place of talking with your doctor about your medical condition or your treatment. Please also read the Package Leaflet carefully before starting your injection and discuss any questions you may have with your doctor or nurse.

The Tremfya pre-filled syringe is intended for injection under the skin, not into the muscle or vein. After injection, the needle will retract into the body of the device and lock into place.

Storage information
Store in refrigerator at 2°C to 8°C. Do not freeze.

Keep Tremfya and all medicines out of reach of children.
Do not shake the pre-filled syringe at any time.
Pre-filled syringe at-a-glance

Before injection

- **Plunger**
  *Do not* hold or pull plunger at any time.

- **Safety guard**

- **Finger flange**

- **Body**
  Hold syringe body **below** finger flange.

- **Viewing window**

- **Needle cover**
  *Do not* remove until you are ready to inject Tremfya (See step 2).
After injection

You will need these supplies:
• 1 Alcohol swab
• 1 Cotton ball or gauze pad
• 1 Adhesive bandage
• 1 Sharps container (See step 3)
1. Prepare for your injection

Inspect carton
Remove carton with the pre-filled syringe from the refrigerator.
Keep the pre-filled syringe in the carton and let it sit on a flat surface at room temperature for at least 30 minutes before use.
Do not warm any other way.
Check the expiry date (‘EXP’) on the back panel of the carton.
Do not use if the expiry date has passed.
Do not inject if the perforations on the carton are broken.
Call your doctor or pharmacist for a refill.

Choose injection site
Select from the following areas for your injection:
• Front of thighs (recommended)
• Lower abdomen
  Do not use the 5-centimetre area around your belly-button.
• Back of upper arms (if a caregiver is giving you the injection)
Do not inject into skin that is tender, bruised, red, scaly or hard.
Do not inject into areas with scars or stretch marks.
Clean injection site
Wash your hands well with soap and warm water.
Wipe your chosen injection site with an alcohol swab and allow it to dry.
**Do not** touch, fan or blow on the injection site after you have cleaned it.

Inspect liquid
Take the pre-filled syringe out of the carton.
Check the liquid in the viewing window. It should be clear to slightly yellow and may contain tiny white or clear particles. You may also see one or more air bubbles.
This is normal.
**Do not** inject if the liquid is cloudy or discoloured, or has large particles. If you are uncertain, call your doctor or pharmacist for a refill.
Remove needle cover
Hold syringe by the body and pull needle cover straight off.
It is normal to see a drop of liquid.
Inject within 5 minutes of removing the needle cover.
Do not put needle cover back on, as this may damage the needle.
Do not touch needle or let it touch any surface.
Do not use the Tremfya pre-filled syringe if it is dropped. Call your doctor or pharmacist for a refill.

Position fingers and insert needle
Place your thumb, index and middle fingers directly under the finger flange, as shown.
Do not touch plunger or area above finger flange as this may cause the needle safety device to activate.
Use your other hand to pinch skin at the injection site. Position syringe at about a 45 degree angle to the skin.
It is important to pinch enough skin to inject under the skin and not into the muscle.
Insert needle with a quick, dart-like motion.
Release pinch and reposition hand
Use your free hand to grasp the body of the syringe.

Press plunger
Place thumb from the opposite hand on the plunger and press the plunger **all the way down until it stops**.

Release pressure from plunger
The safety guard will cover the needle and lock into place, removing the needle from your skin.
3. After your injection

Throw the used pre-filled syringe away
Put your used syringe in a sharps disposal container right away after use.
Make sure you dispose of the bin as instructed by your doctor or nurse when the container is full.

Check injection site
There may be a small amount of blood or liquid at the injection site. Hold pressure over your skin with a cotton ball or gauze pad until any bleeding stops.
Do not rub the injection site.
If needed, cover injection site with a bandage.
Your injection is now complete!

Need help?
Call your doctor to talk about any questions you may have. For additional assistance or to share your feedback refer to the Package Leaflet for your local representative contact information.
Package leaflet: Information for the user

Tremfya 100 mg solution for injection in pre-filled pen

guselkumab

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Tremfya is and what it is used for
2. What you need to know before you use Tremfya
3. How to use Tremfya
4. Possible side effects
5. How to store Tremfya
6. Contents of the pack and other information

1. What Tremfya is and what it is used for

Tremfya contains the active substance guselkumab which is a type of protein called a monoclonal antibody.

This medicine works by blocking the activity of a protein called IL-23, which is present at increased levels in people with psoriasis and psoriatic arthritis.

**Plaque Psoriasis**

Tremfya is used to treat adults with moderate to severe “plaque psoriasis”, an inflammatory condition affecting the skin and nails.

Tremfya can improve the condition of the skin and appearance of nails and reduce symptoms, such as scaling, shedding, flaking, itching, pain and burning.

**Psoriatic arthritis**

Tremfya is used to treat a condition called “psoriatic arthritis”, an inflammatory disease of the joints, often accompanied by plaque psoriasis. If you have psoriatic arthritis you will first be given other medicines. If you do not respond well enough to these medicines or in case of intolerance, you will be given Tremfya to reduce the signs and symptoms of the disease. Tremfya can be used alone or with another medicine named methotrexate.

Using Tremfya in psoriatic arthritis will benefit you by reducing the signs and symptoms of the disease, slowing down the damage to the cartilage and bone of the joints and improving your ability to do normal daily activities.
2. What you need to know before you use Tremfya

Do not use Tremfya

- if you are allergic to guselkumab or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice before using Tremfya.
- If you have an active infection, including active tuberculosis.

Warnings and precautions
Talk to your doctor, pharmacist or nurse before using Tremfya:

- if you are being treated for an infection;
- if you have an infection that does not go away or that keeps coming back;
- if you have tuberculosis or have been in close contact with someone with tuberculosis;
- if you think you have an infection or have symptoms of an infection (see below under ‘Look out for infections and allergic reactions’);
- if you have recently had a vaccination or if you are due to have a vaccination during treatment with Tremfya.

If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before using Tremfya.

As directed by your doctor, you may need blood tests to check if you have high levels of liver enzymes before you start taking Tremfya and when using it. Increases in liver enzymes may occur more frequently in patients receiving Tremfya every 4 weeks than in patients receiving Tremfya every 8 weeks (see “How to use Tremfya” in section 3).

Look out for infections and allergic reactions
Tremfya can potentially cause serious side effects, including allergic reactions and infections. You must look out for signs of these conditions while you are taking Tremfya.

Signs of infections may include fever or flu like symptoms; muscle aches; cough; shortness of breath; burning when you urinate or urinating more often than usual; blood in your phlegm (mucus); weight loss; diarrhoea or stomach pain; warm, red, or painful skin or sores on your body which are different from your psoriasis.

Serious allergic reactions, which can include the following symptoms, swollen face, lips, mouth, tongue or throat, difficulty swallowing or breathing and hives, have occurred with Tremfya (see “Serious side effects” in section 4).

Stop using Tremfya and tell your doctor or seek medical help immediately if you notice any signs indicating a possible serious allergic reaction or an infection

Children and adolescents
Tremfya is not recommended for children and adolescents under 18 years of age because it has not been studied in this age group.

Other medicines and Tremfya
Tell your doctor or pharmacist:

- if you are using, have recently used or might use any other medicines.
- if you recently had or are due to have a vaccination. You should not be given certain types of vaccines (live vaccines) while using Tremfya.

Pregnancy and breast-feeding

- Tremfya should not be used in pregnancy as the effects of this medicine in pregnant women are not known. If you are a woman of childbearing potential, you are advised to avoid becoming pregnant and must use adequate contraception while using Tremfya and for at least 12 weeks...
after the last Tremfya dose. Talk to your doctor if you are pregnant, think you may be pregnant or are planning to have a baby.

- Talk to your doctor if you are breast-feeding or are planning to breast-feed. You and your doctor should decide if you will breast-feed or use Tremfya.

**Driving and using machines**

Tremfya is unlikely to influence your ability to drive and use machines.

### 3. How to use Tremfya

Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

**How much Tremfya is given and for how long**

Your doctor will decide for how long you need to use Tremfya.

- **Plaque psoriasis**
  - The dose is 100 mg (the content of 1 pre-filled pen) given by injection under the skin (subcutaneous injection). This may be given by your doctor or nurse.
  - After the first dose, you will have the next dose 4 weeks later, and then every 8 weeks.

- **Psoriatic arthritis**
  - The dose is 100 mg (the content of 1 pre-filled pen) given by injection under the skin (subcutaneous injection). This may be given by your doctor or nurse.
  - After the first dose, you will receive the next dose 4 weeks later, and then every 8 weeks. For some patients, after the first dose, Tremfya may be given every 4 weeks. Your doctor will decide how often you may receive Tremfya.

At the start, your doctor or nurse will inject Tremfya. However, you may decide together with your doctor to give Tremfya yourself in which case you will get the appropriate training on how to inject Tremfya. Talk to your doctor or nurse if you have any questions about giving yourself an injection. It is important not to try to inject yourself until you have been trained by your doctor or nurse.

For detailed instructions on how to use Tremfya, carefully read the ‘Instructions for use’ leaflet before use, which is included in the carton.

**If you use more Tremfya than you should**

If you have received more Tremfya than you should or the dose has been given sooner than prescribed, inform your doctor.

**If you forget to use Tremfya**

If you have forgotten to inject a dose of Tremfya, inform your doctor.

**If you stop using Tremfya**

You should not stop using Tremfya without speaking to your doctor first. If you stop treatment, your symptoms may come back.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

### 4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

**Serious side effects**

Tell your doctor or seek medical help immediately if you get any of the following side effects:
**Possible serious allergic reaction** (may affect up to 1 in 100 people) - the signs may include:
- difficulty breathing or swallowing
- swelling of the face, lips, tongue or throat
- severe itching of the skin, with a red rash or raised bumps

**Other side effects**
The following side effects are all mild to moderate. If any of these side effects becomes severe, tell your doctor, pharmacist or nurse immediately.

**Very common** (may affect more than 1 in 10 people)
- respiratory tract infections

**Common** (may affect up to 1 in 10 people)
- headache
- joint pain (arthralgia)
- diarrhoea
- redness, irritation or pain at the injection site
- increased level of liver enzymes in the blood

**Uncommon** (may affect up to 1 in 100 people)
- allergic reaction
- skin rash
- decreased number of a type of white blood cell called neutrophils
- herpes simplex infections
- fungal infection of the skin, for instance between the toes (e.g., athlete’s foot)
- stomach flu (gastroenteritis)
- hives

**Reporting of side effects**
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store Tremfya**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the pre-filled pen label and on the outer carton after “EXP”. The expiry date refers to the last day of that month.

Keep the pre-filled pen in the outer carton in order to protect from light.

Store in a refrigerator (2°C–8°C). Do not freeze.

Do not shake.

Do not use this medicine if you notice that the medicine is cloudy or discoloured, or contains large particles. Before use, remove the carton from the refrigerator and keep the pre-filled pen inside the carton and allow to reach room temperature by waiting for 30 minutes.

This medicine is for single use only. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information

What Tremfya contains
- The active substance is guselkumab. Each pre-filled pen contains 100 mg of guselkumab in 1 mL solution.
- The other ingredients are histidine, histidine monohydrochloride monohydrate, polysorbate 80, sucrose and water for injections.

What Tremfya looks like and contents of the pack
Tremfya is a clear, colourless to light yellow solution for injection (injection). It is available in packs containing one pre-filled pen and in multipacks comprising 2 cartons, each containing 1 pre-filled pen. Not all pack sizes may be marketed.

Marketing Authorisation Holder
Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium

Manufacturer
Janssen Biologics B.V.
Einsteinweg 101
2333CB Leiden
The Netherlands

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien
Janssen-Cilag NV
Tel/Tél: +32 14 64 94 11
janssen@jacbe.jnj.com

Lietuva
UAB "JOHNSON & JOHNSON"
Tel: +370 5 278 68 88
lt@its.jnj.com

България
„Джонсън & Джонсън България” ЕООД
Тел.: +359 2 489 94 00
jjsafety@its.jnj.com

Magyarország
Janssen-Cilag Kft.
Tel.: +36 1 884 2858
janssenuhu@its.jnj.com

Лазурбюрг/Luxembourg
Janssen-Cilag NV
Tel/Tél: +32 14 64 94 11
janssen@jacbe.jnj.com

Danmark
Janssen-Cilag A/S
Tlf: +45 45 94 8282
jacdk@its.jnj.com

Malta
AM MANGION LTD.
Tel: +356 2397 6000

Deutschland
Janssen-Cilag GmbH
Tel: +49 2137 955 955
jancil@its.jnj.com

Nederland
Janssen-Cilag B.V.
Tel: +31 76 711 1111
janssen@jacnl.jnj.com
This leaflet was last revised in

Detailed information on this medicine is available on the European Medicines Agency web site:
Instructions for use
Tremfya
Pre-filled pen

Important
If your doctor decides that you or a caregiver may be able to give your injections of Tremfya at home, you should receive training on the right way to prepare and inject Tremfya using the pre-filled pen. Please read these Instructions for use before using the Tremfya pre-filled pen and each time you get a new pre-filled pen. There may be new information. This instruction guide does not take the place of talking with your doctor about your medical condition or your treatment. Please also read the Package Leaflet carefully before starting your injection and discuss any questions you may have with your doctor or nurse.

Storage information
Store in refrigerator at 2° to 8°C.
Do not freeze.
Keep Tremfya and all medicines out of reach of children.
Do not shake your pre-filled pen at any time.

Need help?
Call your doctor to talk about any questions you may have. For additional assistance or to share your feedback refer to the Package Leaflet for your local representative contact information.
Pre-filled pen at-a-glance

You will need these supplies:
• 1 Alcohol swab
• 1 Cotton ball or gauze pad
• 1 Adhesive bandage
• 1 Sharps container (See step 3)
1. Prepare for your injection

Inspect carton
Remove carton with the pre-filled pen from the refrigerator. Keep pre-filled pen in the carton and let it sit on a flat surface at room temperature for at least 30 minutes before use. Do not warm any other way.

Check the expiry date (‘EXP’) on the carton. Do not use if the expiry date has passed. Do not inject if perforations on the carton are broken. Call your doctor or pharmacist for a new pre-filled pen.

Choose injection site
Select from the following areas for your injection:

- **Front of thighs** (recommended)
- Lower abdomen
  - Do not use the 5-centimetre area around your belly-button.
- Back of upper arms (if a caregiver is giving you the injection)

Do not inject into skin that is tender, bruised, red, scaly, hard or has scars or stretch marks.
Wash hands
Wash your hands well with soap and warm water.

Clean injection site
Wipe your chosen injection site with an alcohol swab and allow it to dry.
**Do not** touch, fan or blow on the injection site after you have cleaned it.

Inspect liquid in window
Take the pre-filled pen out of the carton.
Check the liquid in the window. It should be clear to slightly yellow and may contain tiny white or clear particles. You may also see one or more air bubbles.
This is normal.
**Do not** inject if the liquid is cloudy or discoloured, or has large particles. If you are uncertain, call your doctor or pharmacist for a new pre-filled pen.
2. Inject Tremfya using the pre-filled pen

Twist and pull off bottom cap
Keep hands away from the needle guard after the cap is removed.

Inject within 5 minutes of removing the cap.
Do not put the cap back on, this could damage the needle.

Do not use the pre-filled pen if it is dropped after removing the cap.
Call your doctor or pharmacist for a new pre-filled pen.

Place on skin
Position the pre-filled pen straight onto the skin (about 90 degrees relative to injection site).
**Push handle straight down**
Medication injects as you push down. Do this at a speed that is comfortable for you. **Do not** lift the pre-filled pen during the injection. The needle guard will lock and the full dose will not be delivered.

**Complete injection**
Injection is complete when the handle is pushed all the way down, you hear a click, and the green body is no longer visible.

**Lift straight up**
The yellow band indicates that the needle guard is locked.
3. After your injection

**Throw the used pre-filled pen away**
Put your used pre-filled pen in a sharps disposal container right away after use.
Make sure you dispose of the bin as instructed by your doctor or nurse when the container is full.

**Check injection site**
There may be a small amount of blood or liquid at the injection site. Hold pressure over your skin with a cotton ball or gauze pad until any bleeding stops.
**Do not** rub the injection site.
If needed, cover injection site with a bandage.
Your injection is now complete!